Boston biotech resTORbio raised $40 million aimed at taking its lead candidate for respiratory tract infections in elderly patients into phase 3.

AstraZeneca doubles down on Chinese business through a new drug development joint venture with a state-backed private equity firm.

Germano takes up the position 8 months after a shift in focus at Intrexon led him to give up the president post at the synthetic biology company.

Immunomedics has drawn a firm line under the disruption among its top management in recent months by hiring biotech veteran Michael Pehl.

Shanghai-based biotech EOC Pharma has raised $32 million from Chinese investors to help it bring a series of cancer drugs to market.

We kick off a new long form series assessing the life science industry from its leaders with ex-Teva chief Jeremy Levin.

Aimmune chief Stephen Dilly, M.B.B.S., Ph.D., is calling it a day.

A tax credit that allows biopharma companies to recoup some of the cost of developing drugs for rare diseases could be abolished if a Republican tax reform…